BIRC5 and hepatocellular carcinoma: The previous research pointed out that dovitinib downregulates the p-STAT3 and subsequently reduced the levels of expression of STAT3-related proteins Mcl-1, survivin, and cyclin D1 in a time-dependent manner in human hepatocellular carcinoma (HCC) [22].